Health technology assessment : HTA
-
Health Technol Assess · May 2016
Review Meta AnalysisNeuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · May 2016
Review Meta AnalysisA systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression.
Postnatal depression (PND) is a major depressive disorder in the year following childbirth, which impacts on women, their infants and their families. A range of interventions has been developed to prevent PND. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Jul 2015
Review Meta AnalysisClinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems: a systematic review and meta-analysis.
Services have variable practices for identifying and providing interventions for 'severe attachment problems' (disorganised attachment patterns and attachment disorders). Several government reports have highlighted the need for better parenting interventions in at-risk groups. This report was commissioned to evaluate the clinical effectiveness and cost-effectiveness of parenting interventions for children with severe attachment problems (the main review). One supplementary review explored the evaluation of assessment tools and a second reviewed 10-year outcome data to better inform health economic aspects of the main review. ⋯ The National Institute for Health Research Health Technology Assessment programme.
-
Health Technol Assess · Mar 2015
Review Meta AnalysisThe clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation.
Idiopathic pulmonary fibrosis (IPF) is a life-limiting lung disease that generally affects people over 60 years old. The main symptoms are shortness of breath and cough, and as the disease progresses there is a considerable impact on day-to-day life. Few treatments are currently available. ⋯ The National Institute for Health Research Health Technology Assessment programme.